keyword
MENU ▼
Read by QxMD icon Read
search

review prostate cancer

keyword
https://www.readbyqxmd.com/read/28819727/abiraterone-acetate-a-review-in-metastatic-castration-resistant-prostrate-cancer
#1
Lesley J Scott
Oral abiraterone acetate (Zytiga(®)) is a selective inhibitor of CYP17 and thereby inhibits androgen biosynthesis, with androgen signalling crucial in the progression from primary to metastatic prostate cancer (PC) and subsequently, in the development of metastatic castration-resistant PC (mCRPC). In large phase 3 trials and in the clinical practice setting, oral abiraterone acetate in combination with prednisone was an effective treatment and had an acceptable, manageable tolerability and safety profile in chemotherapy-naive and docetaxel-experienced men with mCRPC...
August 17, 2017: Drugs
https://www.readbyqxmd.com/read/28819719/activity-of-cabazitaxel-in-patients-with-metastatic-castration-resistant-prostate-cancer-after-treatment-with-single-or-dual-regimens-of-novel-androgen-receptor-targeting-agents
#2
Yukari Bando, Nobuyuki Hinata, Tomoaki Terakawa, Junya Furukawa, Ken-Ichi Harada, Yuzo Nakano, Masato Fujisawa
The purpose of this study was to evaluate the efficacy of cabazitaxel for patients with metastatic castration-resistant prostate cancer (mCRPC) after sequential therapy with docetaxel (DTX) and single or dual regimens of novel androgen receptor-axis-targeted (ARAT) agents. We retrospectively reviewed 84 consecutive patients treated with cabazitaxel at Kobe University Hospital and related hospitals from September 2014 to September 2016. The association of each prognostic parameter with progression-free survival (PFS) was evaluated, including the sequence of therapy...
August 17, 2017: Medical Oncology
https://www.readbyqxmd.com/read/28818491/cryotherapy-versus-high-intensity-focused-ultrasound-for-treating-prostate-cancer-oncological-and-functional-results
#3
F Donis Canet, M D Sánchez Gallego, F Arias Fúnez, G Duque Ruíz, I Laso, J Brasero Burgos, J Lorca Álvaro, V Gómez Dos Santos, R Rodríguez Patrón, F J Burgos Revilla
CONTEXT AND OBJECTIVE: The increasingly early diagnosis of prostate cancer requires a search for therapeutic alternatives with good oncological results that in turn facilitate a good long-term quality of life. This review analyses 2 minimally invasive therapies for treating localised prostate cancer in terms of oncological and functional results, as well as the complications resulting from the therapies. ACQUISITION OF EVIDENCE: A systematic literature review was conducted of the treatment of localised prostate cancer with 2 ablative techniques as the primary therapy: cryosurgery or cryotherapy and high intensity focused ultrasound (HIFU)...
August 14, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/28818014/cytoreductive-prostatectomy-in-metastatic-prostate-cancer-a-systematic-review
#4
Joachim Aidt Becker, Kasper Drimer Berg, Martin Andreas Røder, Klaus Brasso, Peter Iversen
The impact of cytoreductive radical prostatectomy on oncological outcome in patients with prostate cancer and limited number of bone metastases is unclear. Data from cancer registries, multi-institutional databases and a single institutional case-control study indicate a possible benefit of combined cytoreduction and hormonal therapy compared to hormonal therapy alone. However, the results may be biased by a number of factors. The evidence from studies on cytoreductive prostatectomy is reviewed.
August 18, 2017: Scandinavian Journal of Urology
https://www.readbyqxmd.com/read/28817298/radical-prostatectomy-innovation-and-outcomes-at-military-and-civilian-institutions
#5
Jeffrey J Leow, Joel S Weissman, Linda Kimsey, Andrew Hoburg, Lorens A Helmchen, Wei Jiang, Nathanael Hevelone, Stuart R Lipsitz, Louis L Nguyen, Steven L Chang
OBJECTIVES: Limited data are available regarding the impact of the type of healthcare delivery system on technology diffusion and associated clinical outcomes. We assessed the adoption of minimally invasive radical prostatectomy (MIRP), a recent clinical innovation, and whether this adoption altered surgical morbidity for prostate cancer surgery. STUDY DESIGN: Retrospective review of administrative data from TRICARE, the healthcare program of the United States Military Health System...
June 2017: American Journal of Managed Care
https://www.readbyqxmd.com/read/28816716/novel-androgen-axis-systemic-therapies-for-metastatic-hormone-sensitive-prostate-cancer
#6
Andrew W Hahn, Peter Hale, Nityam Rathi, Neeraj Agarwal
PURPOSE OF REVIEW: Upfront docetaxel and androgen deprivation therapy (ADT) has improved outcomes over ADT alone in men with metastatic hormone-sensitive prostate cancer (mHSPC). Here in, we review the emerging role of novel androgen axis inhibitors in the treatment of men with mHSPC. RECENT FINDINGS: Recently two studies, LATITUDE and STAMPEDE arm G, showed improved survival with addition of abiraterone acetate with prednisone or prednisolone to ADT in men with hormone-naïve advanced prostate cancer...
August 14, 2017: Current Opinion in Urology
https://www.readbyqxmd.com/read/28816713/radiation-therapy-to-the-primary-in-metastatic-prostate-cancer-palliation-only-or-altering-tumor-biology
#7
Pierre Blanchard, Alberto Bossi, Karim Fizazi
PURPOSE OF REVIEW: Despite improvement in systemic treatment, the prognosis of men with de novo metastatic prostate cancer remains poor. Treating the local disease may not only reduce the occurrence of local urologic symptoms, but also slow the metastatic process, either by reducing the seeding from the primary tumor or by altering the microenvironment and thus minimizing the formation of new metastatic sites. RECENT FINDINGS: Retrospective and population-based studies have suggested that the addition of local treatment to systemic therapy may improve survival in this patient group...
August 14, 2017: Current Opinion in Urology
https://www.readbyqxmd.com/read/28816549/implications-of-bcl-2-and-its-interplay-with-other-molecules-and-signaling-pathways-in-prostate-cancer-progression
#8
Ju-Ha Kim, Hyemin Lee, Eun Ah Shin, Dong Hee Kim, Jhin Baek Choi, Sung-Hoon Kim
Among several genetic alterations involved in the progression of prostate cancer, B cell lymphoma gene number 2 (BCL-2) is an important target molecule in the progression of androgen-independent prostate cancer (AIPC) after androgen ablation or castration. Nevertheless, the molecular mechanism of BCL-2 in prostate cancer progression remains elusive and controversial. In the current review, we discuss the critical role of BCL-2 in the carcinogenesis of prostate cancer with experimental evidences on the BCL-2 molecular networks in AIPC and androgen-dependent prostate cancer (ADPC) and subsequently suggest perspective research targeting BCL-2...
August 17, 2017: Expert Opinion on Therapeutic Targets
https://www.readbyqxmd.com/read/28815924/urinary-micrornas-for-prostate-cancer-diagnosis-prognosis-and-treatment-response-are-we-there-yet
#9
REVIEW
Ovidiu Balacescu, Bogdan Petrut, Oana Tudoran, Dragos Feflea, Loredana Balacescu, Andrei Anghel, Ioan O Sirbu, Edward Seclaman, Catalin Marian
Prostate cancer (PCa) remains one of the leading causes of cancer-related deaths in men. Despite the tremendous progress in research over the years, a suitable minimally invasive PCa biomarker is yet to be discovered. The recent advances regarding the roles of microRNAs as biomarkers has allowed for their study in PCa as well, especially as blood-based markers. However, there are several studies that used urine as biological sample to evaluate microRNAs as biomarkers for PCa diagnosis, prognosis, and treatment response, which were reviewed herein...
August 16, 2017: Wiley Interdisciplinary Reviews. RNA
https://www.readbyqxmd.com/read/28814898/reducing-rectal-injury-in-men-receiving-prostate-cancer-radiation-therapy-current-perspectives
#10
REVIEW
Nicholas A Serrano, Noah S Kalman, Mitchell S Anscher
Dose escalation is now the standard of care for the treatment of prostate cancer with radiation therapy. However, the rectum tends to be the dose-limiting structure when treating prostate cancer, given its close proximity. Early and late toxicities can occur when the rectum receives large doses of radiation therapy. New technologies allow for prevention of these toxicities. In this review, we examine the evidence that supports various dose constraints employed to prevent these rectal injuries from occurring...
2017: Cancer Management and Research
https://www.readbyqxmd.com/read/28814451/androgen-deprivation-and-immunotherapy-for-the-treatment-of-prostate-cancer
#11
Melissa Gamat, Douglas G McNeel
Prostate cancer is the most common newly diagnosed malignancy in men, and the second most common cause of cancer-related death in the United States. The primary treatment for recurrent prostate cancer is androgen deprivation, and this therapy is typically continued life-long for patients with metastatic prostate cancer. Androgens and androgen deprivation have profound effects on the immune system, a finding that has become more appreciated in an era where immune-based treatments for cancer are being increasingly explored...
August 16, 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28814252/bone-imaging-in-metastatic-castration-resistant-prostate-cancer-where-do-we-stand
#12
Petros Sountoulides, Linda Metaxa
We are witnessing an era of increased clinical interest in metastatic castration-resistant prostate cancer, both in terms of treatment and also in terms of imaging options. This surge in interest is attributed to the recent developments in treatments for metastatic prostate cancer that are able to confer a significant survival advantage. We are therefore anticipating an increase in the number of patients that we will need to treat at this disease stage. Imaging is undoubtedly crucial in monitoring disease response to treatment and progression...
August 16, 2017: Current Radiopharmaceuticals
https://www.readbyqxmd.com/read/28813783/comprehensive-overview-of-prostatitis
#13
REVIEW
Farhan Ullah Khan, Awais Ullah Ihsan, Hidayat Ullah Khan, Ruby Jana, Junaid Wazir, Puregmaa Khongorzul, Muhammad Waqar, Xiaohui Zhou
Prostatitis is a common urinary tract syndrome that many doctors find problematic to treat effectively. It is the third most commonly found urinary tract disease in men after prostate cancer and Benign Prostate Hyperplasia (BPH). Prostatitis may account for 25% of all office visits made to the urological clinics complaining about the genital and urinary systems all over the world. In the present study, we classified prostatitis and comprehensively elaborated the etiology, pathogenesis, diagnosis, and treatment of acute bacterial prostatitis (category I), chronic bacterial prostatitis (category II), chronic pelvic pain syndrome (CPPS) (category III), and asymptomatic prostatitis (category IV)...
August 12, 2017: Biomedicine & Pharmacotherapy, Biomédecine & Pharmacothérapie
https://www.readbyqxmd.com/read/28813112/what-do-cochrane-systematic-reviews-say-about-the-clinical-effectiveness-of-screening-and-diagnostic-tests-for-cancer
#14
André Tito Pereira Bueno, Vladimir Lisboa Capelasso, Rafael Leite Pacheco, Carolina de Oliveira Cruz Latorraca, Tiago Biachi de Castria, Daniela Vianna Pachito, Rachel Riera
CONTEXT AND OBJECTIVE: The purpose of screening tests for cancer is to detect it at an early stage in order to increase the chances of treatment. However, their unrestrained use may lead to unnecessary examinations, overdiagnosis and higher costs. It is thus necessary to evaluate their clinical effects in terms of benefits and harm. DESIGN AND SETTING: Review of Cochrane systematic reviews, carried out in the Discipline of Evidence-Based Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo...
July 2017: São Paulo Medical Journal, Revista Paulista de Medicina
https://www.readbyqxmd.com/read/28811991/systematic-review-of-the-outcomes-of-surgical-treatment-of-prostate-metastases-to-the-spine
#15
REVIEW
Michelle J Clarke, Camilo A Molina, Daryl R Fourney, Charles G Fisher, Ziya L Gokaslan, Meic H Schmidt, Laurence D Rhines, Michael G Fehlings, Ilya Laufer, Shreyaskumar R Patel, Y Raja Rampersaud, Jeremy Reynolds, Dean Chou, Chetan Bettegowda, Ehud Mendel, Michael H Weber, Daniel M Sciubba
STUDY DESIGN: Systematic review. OBJECTIVE: Surgical decompression and reconstruction of symptomatic spinal metastases has improved the quality of life in cancer patients. However, most data has been collected on cohorts of patients with mixed tumor histopathology. We systematically reviewed the literature for prognostic factors specific to the surgical treatment of prostate metastases to the spine. METHODS: A systemic review of the literature was conducted to answer the following questions: Question 1...
August 2017: Global Spine Journal
https://www.readbyqxmd.com/read/28808871/african-american-prostate-cancer-disparities
#16
REVIEW
Zachary L Smith, Scott E Eggener, Adam B Murphy
PURPOSE OF REVIEW: The purpose of this review is to examine prostate cancer racial disparities specific to the African-American population. RECENT FINDINGS: African-American men are more likely to be diagnosed with prostate cancer, present at an earlier age; are more likely to have locally advanced or metastatic disease at diagnosis; and have suboptimal outcomes to standard treatments. Prostate cancer treatment requires a nuanced approach, particularly when applying screening, counseling, and management of African-American men...
August 14, 2017: Current Urology Reports
https://www.readbyqxmd.com/read/28808043/allosteric-alterations-in-the-androgen-receptor-and-activity-in-prostate-cancer
#17
REVIEW
Takuma Uo, Stephen R Plymate, Cynthia C Sprenger
Organisms have evolved to generate biological complexity in their proteome and transcriptome from a limited number of genes. This concept holds true for the androgen receptor, which displays a diversity of inclusion/exclusion events in its structural motifs as a mechanism of resistance to the most forefront anti-androgen therapies. More than 20 androgen receptor variants that lack various portions of ligand-binding domain have been identified in human prostate cancer (PCa) samples. Most of the variants are inactive on their own, with a few exceptions displaying constitutive activity...
September 2017: Endocrine-related Cancer
https://www.readbyqxmd.com/read/28807747/pretreatment-3t-multiparametric-mri-staging-predicts-for-biochemical-failure-in-high-risk-prostate-cancer-treated-with-combination-high-dose-rate-brachytherapy-and-external-beam-radiotherapy
#18
John V Hegde, D Jeffrey Demanes, Darlene Veruttipong, Jagdeep Raince, Sang-June Park, Steven S Raman, Nicholas G Nickols, Christopher R King, Amar U Kishan, Michael L Steinberg, Mitchell Kamrava
PURPOSE: To determine whether pretreatment 3T multiparametric MRI (mpMRI) staging impacts biochemical recurrence-free survival (BRFS) or distant metastasis-free survival (DMFS) for men with high-risk prostate cancer treated with combination high-dose-rate (HDR) brachytherapy and external beam radiation therapy (EBRT). MATERIALS AND METHODS: This institutional review board-approved retrospective study included a cohort of 37 men with high-risk prostate cancer treated with HDR brachytherapy and EBRT after 3T mpMRI...
August 11, 2017: Brachytherapy
https://www.readbyqxmd.com/read/28807541/urinary-rna-based-biomarkers-for-prostate-cancer-detection
#19
REVIEW
Filippo Martignano, Lorena Rossi, Antonio Maugeri, Valentina Gallà, Vincenza Conteduca, Ugo De Giorgi, Valentina Casadio, Giuseppe Schepisi
Prostate cancer (PCa) is the commonest malignancy in the male population worldwide. Serum prostate specific antigen (PSA) test is the most important biomarker for the detection, follow-up and therapeutic monitoring of PCa. Defects in PSA specificity have elicited research for new biomarkers to improve early diagnosis and avoid false-positive results. This review evaluates urinary RNA-based biomarkers. Urine is a versatile body fluid for non-invasive biomarker detection in case of urological malignancies. The importance of RNA-based biomarkers has been demonstrated by the current use of PCA3, a long non coding RNA biomarker already approved by the Food and Drugs Administration...
August 11, 2017: Clinica Chimica Acta; International Journal of Clinical Chemistry
https://www.readbyqxmd.com/read/28806263/18f-dcfbc-prostate-specific-membrane-antigen-targeted-pet-ct-imaging-in-localized-prostate-cancer-correlation-with-multiparametric-mri-and-histopathology
#20
Baris Turkbey, Esther Mena, Liza Lindenberg, Stephen Adler, Sandra Bednarova, Rose Berman, Anita T Ton, Yolanda McKinney, Philip Eclarinal, Craig Hill, George Afari, Sibaprasad Bhattacharyya, Ronnie C Mease, Maria J Merino, Paula M Jacobs, Bradford J Wood, Peter A Pinto, Martin G Pomper, Peter L Choyke
PURPOSE: To assess the ability of (N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-F-fluorobenzyl-L-cysteine) (F-DCFBC), a prostate-specific membrane antigen-targeted PET agent, to detect localized prostate cancer lesions in correlation with multiparametric MRI (mpMRI) and histopathology. METHODS: This Health Insurance Portability and Accountability Act of 1996-compliant, prospective, institutional review board-approved study included 13 evaluable patients with localized prostate cancer (median age, 62...
August 12, 2017: Clinical Nuclear Medicine
keyword
keyword
63533
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"